Cargando…

PMON280 Effect of Gender Affirming Hormone Therapy (GAHT) on Adipose Tissue Morphology and Metabolism in Transgender Individuals

BACKGROUND: Circulating sex hormones exert unique effects on metabolism, leading to sexual dimorphism in white adipose tissue distribution and function. The gender affirming hormone therapy (GAHT) or cross-sex hormone therapy (CSHT) for transgender patients lower the endogenous sex hormones while ra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shah, Manasi S, Lee, Charlotte, Guo, Lei, Bryant, Ananda, Ragunton, Jan-Michael, Caldwell, Laura, Xu, Lin, Onodera, Toshiharu, Gordillo, Ruth, Scherer, Philipp E, Soe, Kyaw
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Reproductive Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625626/ http://dx.doi.org/10.1210/jendso/bvac150.1457

Ejemplares similares

RF34 | PMON276 The Effect of Gender Affirming Hormone Therapy (GAHT) on Non-Conventional Cardiovascular Risk Markers in Transgender Men: A Systematic Review
por: Moreira Allgayer, Roberta Martins Costa, et al.
Publicado: (2022)

Effect on Kidney Function During Gender Affirming Hormonal Treatment in Transgender Individuals
por: Maheshwari, Arvind Kumar, et al.
Publicado: (2021)

Prolactinoma in a Male to Female Transgender Woman on Gender Affirming Hormone Therapy
por: Harned, Leighton K, et al.
Publicado: (2021)

SAT394 Over-representation Of Adoptees Among Transgender Subjects Seeking Gender-Affirming-Hormonal-Therapy (GAHT) In A Large Tertiary Medical Center
por: Yaish, Iris, et al.
Publicado: (2023)

MON-195 Trans-transgender Female: Gender Identity Reversal Following Irreversible Gender Affirming Surgeries
por: Korpaisarn, Sira, et al.
Publicado: (2019)

ODP414 Incidence of Suicidal Events in Transgender Patients with Initiation of Gender Affirming Hormone Therapy
por: Elliott, Karma-Jaya, et al.
Publicado: (2022)

Physical and Sociodemographic Features Associated With Quality of Life in Transgender Individuals Using Gender-Affirming Hormone Therapy
por: Da Silva, Eliane Dias, et al.
Publicado: (2021)

Suicidal attempts and non-suicidal self-injury during gender affirming hormone therapy (GAHT) – a case report
por: Puzio, D., et al.
Publicado: (2022)

Cardiovascular Risk Factors in Transgender Women Undergoing Long-Term Gender-Affirming Hormone Therapy: A Cross-Sectional Study
por: Alvares, Leonardo A M, et al.
Publicado: (2021)

“It Wasn’t for the Sake of Me and My Mental Health”: Transgender People’s Perspective on the Role of Mental Health Providers in Initiating Gender-Affirming Hormones - a Qualitative Study
por: Maksutova, Mariam, et al.
Publicado: (2021)

A Cross Sectional Analysis of the Prevalence of Co-Morbidities in Older Transgender Individuals Receiving Hormone Affirming Therapy in Comparison With the General Population
por: Breda, Ido, et al.
Publicado: (2021)

PMON278 Research Priorities of Gender Diverse Adults: What is Most Important to the Community?
por: Kline, Danielle M, et al.
Publicado: (2022)

PMON260 Cost-Effectiveness of Testosterone Treatment for Men with Hypogonadism
por: Jayasena, Channa, et al.
Publicado: (2022)

RF34 | PMON202 The Human Metabolic Profile of Estetrol
por: Gérard, Céline, et al.
Publicado: (2022)

PMON275 GONAD-on-CHIP to study early gonad development and DSD
por: Bashamboo, Anu, et al.
Publicado: (2022)

PMON209 Ceramides Predict Metabolic Response to Metformin in Women with PCOS
por: Sharma, Anu, et al.
Publicado: (2022)

MON-196 Gender-Affirming Hormonal Therapy and Incidence of Metabolic Syndrome and Cardiovascular Events in Patients with Gender Dysphoria
por: Mok, Mary, et al.
Publicado: (2019)

PMON223 Sellar Meningioma in Association with Fertility Treatment, A Case Report
por: Alnahas, Zeinab, et al.
Publicado: (2022)

PMON226 Primary Ovarian Insufficiency: A Case of a Missed Puberty
por: Lin, Jack, et al.
Publicado: (2022)

Sexual & reproductive health information on minor consent forms for pubertal suppression and gender affirming hormones
por: Taylor, Julia, et al.
Publicado: (2023)

SAT422 Gender Affirming Hormone Therapy in a Non-Binary Individual with Swyer Syndrome
por: Yohannan, Jiby M, et al.
Publicado: (2023)

RF10 | PMON221 11-Oxygenated-Androgens in Females with Severe Insulin Resistance
por: Merke, Deborah, et al.
Publicado: (2022)

RF34 | PMON222 Reproductive Hormone Secretion is Increased by Intranasal Kisspeptin in Humans
por: Mills, Edouard G, et al.
Publicado: (2022)

PMON246 Prevalence of Hypertension and Metabolic Syndrome in Women with PCOS from France and Brazil
por: Spritzer, Poli Mara, et al.
Publicado: (2022)

PMON201 The Impact of Menopause on Poor Outcomes in Hospitalized Patients with COVID-19 Infection
por: Toure, Tonslyn, et al.
Publicado: (2022)

Integrated and Gender-Affirming Transgender Clinical Care and Research
por: Reisner, Sari L., et al.
Publicado: (2016)

FRI446 A Case Of 46 XX Testicular Disorder Of Sex Development Presenting As Hypogonadism And Infertility
por: Balachandar, Neeraja, et al.
Publicado: (2023)

PMON228 The Hidden Source of Testosterone Hypersecretion in a Female - a Thirty-Year Journey
por: Yang, Almira, et al.
Publicado: (2022)

OR25-4 Modulatory Effects of Estradiol on the Resting-State Functional Connectivity in Transwomen Following Gender Affirming Surgery
por: Schneider, Maiko, et al.
Publicado: (2019)

RF10 | PMON249 MicroRNA-21 Ablation Exacerbates Androgen-Mediated White Adipose Tissue Dysfunction and Impaired Insulin Signaling in a Mouse Model of Polycystic Ovary Syndrome
por: Rezq, Samar, et al.
Publicado: (2022)

PMON257 Oral Ingestion of Macronutrients Selectively and Variably Decrease Circulating Testosterone Concentration in Healthy Men
por: Iranmanesh, Ali, et al.
Publicado: (2022)

PMON214 Kisspeptin Restores Sexual and Attraction Brain Processing in Women with Hypoactive Sexual Desire Disorder
por: Thurston, Layla, et al.
Publicado: (2022)

RF34 | PMON229 TNFa-Induced Altered miRNA Expression Links to Inflammation in Endometriosis
por: Chowdhury, Indrajit, et al.
Publicado: (2022)

PMON208 METFORMIN, SPIRONOLACTONE AND ORAL CONTRACEPTIVES IN POLYCYSTIC OVARY SYNDROME: A NETWORK META-ANALYSIS
por: Rodriguez-Gutierrez, Rene, et al.
Publicado: (2022)

PMON227 Rare ovarian luteinized fibrothecoma as cause of severe hyperandrogenism in a pre-menopausal woman.
por: Mikkilineni, Pushyami, et al.
Publicado: (2022)

PMON281 PERSISTENT VIRILIZATION AND VASOMOTOR SYMPTOMS IN A TRANSMAN 5-YEARS POST TESTOSTERONE WITHDRAWAL
por: Nemati, Maryam, et al.
Publicado: (2022)

PMON243 Metabolic Disorders Genetically Modify Polycystic Ovary Syndrome through its Candidate Hormones
por: Actkins, Ky’Era, et al.
Publicado: (2022)

The Role of the Endocrinologist in the Gender Adequacy Process and the Barriers for Adequate Transgender Health Care
por: Saliba, Alexandra
Publicado: (2021)

Beyond the Binary: Sexual and Reproductive Health Considerations for Transgender and Gender Expansive Adolescents
por: Lunde, Claire E., et al.
Publicado: (2021)

Clinical pearls of gender-affirming hormone therapy in transgender patients
por: Irving, Amanda, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_u8agq2b9ojqibfp2ueilece3c0